It turned down Pfizer’s Staquis (crisaborole) – also sold as Eucrisa in some markets including the US – as a second-line treatment for mild to moderate atopic dermatitis, and Celgene’s ...
Pfizer also got the nod for Staquis (crisaborole), a topical phosphodiesterase 4 (PDE-4) inhibitor for atopic dermatitis already sold as Eucrisa in the US since 2016. The US drugmaker also had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback